Cargando…

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience

Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability in clinical practice. Methods: We collected data of EGFR-mutated NSCLC patients with liquid biopsy analysis. Data included tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulivi, Paola, Petracci, Elisabetta, Canale, Matteo, Priano, Ilaria, Capelli, Laura, Calistri, Daniele, Chiadini, Elisa, Cravero, Paola, Rossi, Alice, Delmonte, Angelo, Crinò, Lucio, Bronte, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533402/
https://www.ncbi.nlm.nih.gov/pubmed/34680416
http://dx.doi.org/10.3390/biomedicines9101299
_version_ 1784587304215511040
author Ulivi, Paola
Petracci, Elisabetta
Canale, Matteo
Priano, Ilaria
Capelli, Laura
Calistri, Daniele
Chiadini, Elisa
Cravero, Paola
Rossi, Alice
Delmonte, Angelo
Crinò, Lucio
Bronte, Giuseppe
author_facet Ulivi, Paola
Petracci, Elisabetta
Canale, Matteo
Priano, Ilaria
Capelli, Laura
Calistri, Daniele
Chiadini, Elisa
Cravero, Paola
Rossi, Alice
Delmonte, Angelo
Crinò, Lucio
Bronte, Giuseppe
author_sort Ulivi, Paola
collection PubMed
description Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability in clinical practice. Methods: We collected data of EGFR-mutated NSCLC patients with liquid biopsy analysis. Data included test timing, concomitant tissue re-biopsy, therapy change, histology, stage, smoking habits, gender and age. All analyses were performed via a real-time PCR method to analyze EGFR mutations at exons 18, 19, 20 and 21. Variant allele frequency was performed for patients with available sequential EGFR mutation analysis in cfDNA. Overall survival was analyzed through the Kaplan–Meier method. We designed flow charts to show the real-life application of liquid biopsy. Results: We found that liquid biopsy is used in treatment-naïve patients as an alternative to EGFR detection in tumor tissue, and in patients with positive or negative EGFR from tumor biopsy. The majority of liquid biopsy analyses were performed in NSCLC patients who were disease progressive during TKI therapy. The presence of EGFR mutation in cfDNA was associated with a worse prognosis. In two patients, VAF of EGFR mutations in cfDNA was concordant with tumor volume changes. Conclusion: These findings suggest that liquid biopsy for EGFR detection can continue to be useful.
format Online
Article
Text
id pubmed-8533402
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85334022021-10-23 Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience Ulivi, Paola Petracci, Elisabetta Canale, Matteo Priano, Ilaria Capelli, Laura Calistri, Daniele Chiadini, Elisa Cravero, Paola Rossi, Alice Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe Biomedicines Article Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability in clinical practice. Methods: We collected data of EGFR-mutated NSCLC patients with liquid biopsy analysis. Data included test timing, concomitant tissue re-biopsy, therapy change, histology, stage, smoking habits, gender and age. All analyses were performed via a real-time PCR method to analyze EGFR mutations at exons 18, 19, 20 and 21. Variant allele frequency was performed for patients with available sequential EGFR mutation analysis in cfDNA. Overall survival was analyzed through the Kaplan–Meier method. We designed flow charts to show the real-life application of liquid biopsy. Results: We found that liquid biopsy is used in treatment-naïve patients as an alternative to EGFR detection in tumor tissue, and in patients with positive or negative EGFR from tumor biopsy. The majority of liquid biopsy analyses were performed in NSCLC patients who were disease progressive during TKI therapy. The presence of EGFR mutation in cfDNA was associated with a worse prognosis. In two patients, VAF of EGFR mutations in cfDNA was concordant with tumor volume changes. Conclusion: These findings suggest that liquid biopsy for EGFR detection can continue to be useful. MDPI 2021-09-23 /pmc/articles/PMC8533402/ /pubmed/34680416 http://dx.doi.org/10.3390/biomedicines9101299 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ulivi, Paola
Petracci, Elisabetta
Canale, Matteo
Priano, Ilaria
Capelli, Laura
Calistri, Daniele
Chiadini, Elisa
Cravero, Paola
Rossi, Alice
Delmonte, Angelo
Crinò, Lucio
Bronte, Giuseppe
Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
title Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
title_full Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
title_fullStr Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
title_full_unstemmed Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
title_short Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
title_sort liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: thoughts drawn from a real-life experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533402/
https://www.ncbi.nlm.nih.gov/pubmed/34680416
http://dx.doi.org/10.3390/biomedicines9101299
work_keys_str_mv AT ulivipaola liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT petraccielisabetta liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT canalematteo liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT prianoilaria liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT capellilaura liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT calistridaniele liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT chiadinielisa liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT craveropaola liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT rossialice liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT delmonteangelo liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT crinolucio liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience
AT brontegiuseppe liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience